* Pacira Biosciences Inc PCRX.OQ PCRX.O is expected
to show a
rise in quarterly revenue when it reports results on August 2.
* The Tampa Florida-based company is expected to report a
3.1% increase in revenue to $174.604 million from $169.41
million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Pacira Biosciences
Inc is
for earnings of 76 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Pacira
Biosciences Inc is $60, above its last closing price
of $35.78.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 0.62 0.62 0.53 Missed -14.1
Dec. 31 2023 0.82 0.83 0.80 Missed -3.6
Sep. 30 2022 0.71 0.76 0.64 Missed -16.2
Jun. 30 2022 0.81 0.85 0.51 Missed -40.1
Mar. 0.80 0.83 0.64 Missed -23.1
31 2022
Dec. 31 2021 0.82 0.90 0.97 Beat 7.4
Sep. 30 2021 0.65 0.65 0.72 Beat 10.2
Jun. 30 2021 0.79 0.74 0.77 Beat 4.6
This summary was machine generated July 31 at 18:34 GMT. All
figures in US dollars unless otherwise stated